Janice M Santiago-O'Farrill1, S John Weroha2, Xiaonan Hou2, Ann L Oberg3, Ethan P Heinzen3, Matthew J Maurer3, Lan Pang1, Philip Rask1, Ravi K Amaravadi4, Sarah E Becker1, Ignacio Romero5,6, Ma Jesús Rubio6,7, Xavier Matias-Guiu6,8,9, Maria Santacana6,8,9, Antonio Llombart-Cussac6,10, Andrés Poveda5,6, Zhen Lu1, Robert C Bast1. 1. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Oncology, Mayo Clinic, Rochester, Minnesota. 3. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 4. Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania. 5. Valencian Institute of Oncology, Valencia, Spain. 6. Medica Scientia Innovation Research, Barcelona, Spain. 7. Reina Sofia University Hospital of Cordoba, Cordoba, Spain. 8. Arnau de Vilanova University Hospital of Lleida, Lleida Biomedical Research Institute, University of Lleida, Lleida, Spain. 9. Centro de Investigación Biomédica en Red de Cáncer (CIBERNC), Madrid, Spain. 10. Arnau de Vilanova Hospital, Valencia, Spain.
Abstract
BACKGROUND: Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors exhibit promising activity against ovarian cancers, but their efficacy can be limited by acquired drug resistance. This study explores the role of autophagy in regulating the sensitivity of ovarian cancer cells to PARP inhibitors. METHODS: Induction of autophagy was detected by punctate LC3 fluorescence staining, LC3I to LC3II conversion on Western blot analysis, and electron microscopy. Enhanced growth inhibition and apoptosis were observed when PARP inhibitors were used with hydroxychloroquine, chloroquine (CQ), or LYS05 to block the hydrolysis of proteins and lipids in autophagosomes or with small interfering RNA against ATG5 or ATG7 to prevent the formation of autophagosomes. The preclinical efficacy of the combination of CQ and olaparib was evaluated with a patient-derived xenograft (PDX) and the OVCAR8 human ovarian cancer cell line. RESULTS: Four PARP inhibitors (olaparib, niraparib, rucaparib, and talazoparib) induced autophagy in a panel of ovarian cancer cells. Inhibition of autophagy with CQ enhanced the sensitivity of ovarian cancer cells to PARP inhibitors. In vivo, olaparib and CQ produced additive growth inhibition in OVCAR8 xenografts and a PDX. Olaparib inhibited PARP activity, and this led to increased reactive oxygen species (ROS) and an accumulation of γ-H2AX. Inhibition of autophagy also increased ROS and γ-H2AX and enhanced the effect of olaparib on both entities. Treatment with olaparib increased phosphorylation of ATM and PTEN while decreasing the phosphorylation of AKT and mTOR and inducing autophagy. CONCLUSIONS: PARP inhibitor-induced autophagy provides an adaptive mechanism of resistance to PARP inhibitors in cancer cells with wild-type BRCA, and a combination of PARP inhibitors with CQ or other autophagy inhibitors could improve outcomes for patients with ovarian cancer.
BACKGROUND:Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors exhibit promising activity against ovarian cancers, but their efficacy can be limited by acquired drug resistance. This study explores the role of autophagy in regulating the sensitivity of ovarian cancer cells to PARP inhibitors. METHODS: Induction of autophagy was detected by punctate LC3 fluorescence staining, LC3I to LC3II conversion on Western blot analysis, and electron microscopy. Enhanced growth inhibition and apoptosis were observed when PARP inhibitors were used with hydroxychloroquine, chloroquine (CQ), or LYS05 to block the hydrolysis of proteins and lipids in autophagosomes or with small interfering RNA against ATG5 or ATG7 to prevent the formation of autophagosomes. The preclinical efficacy of the combination of CQ and olaparib was evaluated with a patient-derived xenograft (PDX) and the OVCAR8humanovarian cancer cell line. RESULTS: Four PARP inhibitors (olaparib, niraparib, rucaparib, and talazoparib) induced autophagy in a panel of ovarian cancer cells. Inhibition of autophagy with CQ enhanced the sensitivity of ovarian cancer cells to PARP inhibitors. In vivo, olaparib and CQ produced additive growth inhibition in OVCAR8 xenografts and a PDX. Olaparib inhibited PARP activity, and this led to increased reactive oxygen species (ROS) and an accumulation of γ-H2AX. Inhibition of autophagy also increased ROS and γ-H2AX and enhanced the effect of olaparib on both entities. Treatment with olaparib increased phosphorylation of ATM and PTEN while decreasing the phosphorylation of AKT and mTOR and inducing autophagy. CONCLUSIONS:PARP inhibitor-induced autophagy provides an adaptive mechanism of resistance to PARP inhibitors in cancer cells with wild-type BRCA, and a combination of PARP inhibitors with CQ or other autophagy inhibitors could improve outcomes for patients with ovarian cancer.
Authors: S John Weroha; Marc A Becker; Sergio Enderica-Gonzalez; Sean C Harrington; Ann L Oberg; Matthew J Maurer; Sarah E Perkins; Mariam AlHilli; Kristina A Butler; Sarah McKinstry; Stephanie Fink; Robert B Jenkins; Xiaonan Hou; Kimberly R Kalli; Karin M Goodman; Jann N Sarkaria; Beth Y Karlan; Amanika Kumar; Scott H Kaufmann; Lynn C Hartmann; Paul Haluska Journal: Clin Cancer Res Date: 2014-01-07 Impact factor: 12.531
Authors: Manuel Hidalgo; Frederic Amant; Andrew V Biankin; Eva Budinská; Annette T Byrne; Carlos Caldas; Robert B Clarke; Steven de Jong; Jos Jonkers; Gunhild Mari Mælandsmo; Sergio Roman-Roman; Joan Seoane; Livio Trusolino; Alberto Villanueva Journal: Cancer Discov Date: 2014-07-15 Impact factor: 39.397
Authors: Irving Balbuena-Rebolledo; Astrid M Rivera-Antonio; Yudibeth Sixto-López; José Correa-Basurto; Martha C Rosales-Hernández; Jessica Elena Mendieta-Wejebe; Francisco J Martínez-Martínez; Ivonne María Olivares-Corichi; José Rubén García-Sánchez; Juan Alberto Guevara-Salazar; Martiniano Bello; Itzia I Padilla-Martínez Journal: Pharmaceuticals (Basel) Date: 2022-05-31
Authors: Arun Kanakkanthara; Xiaonan Hou; Thomas L Ekstrom; Valentina Zanfagnin; Amelia M Huehls; Rebecca L Kelly; Husheng Ding; Melissa C Larson; George Vasmatzis; Ann L Oberg; Scott H Kaufmann; Aaron S Mansfield; S John Weroha; Larry M Karnitz Journal: Cancer Res Date: 2021-11-22 Impact factor: 13.312
Authors: Kaihua Zhong; Dong Chen; Zhiming Wu; Xiaohong Wang; Bin Pan; Nanhui Chen; Weifeng Zhong Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2020-11-30
Authors: Laura Jankó; Zsanett Sári; Tünde Kovács; Gréta Kis; Magdolna Szántó; Miklós Antal; Gábor Juhász; Péter Bai Journal: Cells Date: 2020-02-07 Impact factor: 6.600